Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • scifiction
    Junior Member
    • Oct 2016
    • 3

    Help in analyzing RNA Seq data

    I have final gene expression data (RNA Sequencing), four treatments in duplicate. I want to analyze this data for cumulative frequency distribution and heatmaps. How should I proceed? This is first time I am dealing with such a data.
  • Persistent LABS
    Member
    • Apr 2016
    • 21

    #2
    Hi scifiction,
    If you are comfortable in R, you can use DESeq2 package and perform differential expression analysis. In that case, this link might help you: https://bioconductor.org/packages/re...doc/DESeq2.pdf

    There is another web-server designed for small RNA data analysis. But I guess you can run differential gene expression analysis for your count data under "DE Analysis" tab. Here is the link: https://oasis.dzne.de/small_rna_de.php
    It will give you heatmap and other diagnostic plots.
    Persistent LABS

    Comment

    • scifiction
      Junior Member
      • Oct 2016
      • 3

      #3
      Thanks a lot

      Comment

      • katiadt
        Junior Member
        • Aug 2017
        • 3

        #4
        assembly vs mapping

        Hi guys,
        I'm new here! I'm a PhD student engaged in a transcriptomic project. I have one control sample and four different stressed, all sequenced using HiSeq2000, without replicates. At a first moment, my tutor submitted the analysis to a ver big and famous company, requesting de novo assembly and differential expression analysis. The assembly was not good for me, because there was a low number of assembled transcripts (686, while actually there are 1936 annotated genes) and a very low number of DE genes was found. So, I tried to perform again the analysis using Trinity, as the company done, and I couldn't assemble the transcriptome: I found more than 15.000 trasncripts and many were too short. Furthermore, when I performed a blast against all NCBI database, I found many and many contaminants (i.e. human sequences). So, I tried with other programs (i.e. TransAByss, Velvet-Oases and Rockhopper) but they didn't work correctly. So I leave my tutor's idea of de novo assembly, because the genome of this bacterial strain became available in NCBI and its annotation too. I mapped the reads with STAR using its own genome; I was surprised because the percentages of mapped reads were low. I performed counting with FeatureCounts and did differential analysis with NOISeq (due to the absence of replicates in the experimental design). At a first moment, I used all mapped reads, but I was in a saturation condition, so I found the right compromise using only 10 million of mapped reads from each bam file. About one million resulted unassigned (NoFeatures).
        Finally, I found many DE genes, but I'm frustrated because my results are the opposite of company's results. I did inspect them by an experienced researcher and he told me that I performed the analysis properly.
        What should I think?What should I do? I quarrel with my tutor every day and I'm about to leave the PhD course because the situation is unbearable. Please help me

        Comment

        • katiadt
          Junior Member
          • Aug 2017
          • 3

          #5
          If your replicates are not so good, you can use edgeR that is more robust.

          I ask another type of help: I performed RNA-seq analysis of bacterial transcriptome in four different stressed conditions, mapping the reads on its own genome available in NCBI. Then I used FeatureCounts for reads counting and finally I performed differential analysis with NOISeq R package, because of the absence of replicates.
          Before that, my tutor submitted the analysis to a famous company requiring a de novo assembly (they used the trinity pipeline for assembly and differential analysis).
          I used the same fastq files, and finally I found a larger number of DE genes, but my results are the opposite of company's results. How is it possible? I know that mapping is better than assembly when a reference genome is available and above all I know that the trinity pipeline have some problems for differential analysis, because it uses DESeq or edgeR after quantification by RSEM.
          What do you think about?

          Comment

          Latest Articles

          Collapse

          • mylaser
            Reply to Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by mylaser
            Kheloyar – Everything You Need to Know About Kheloyaar Login and Kheoyar Id
            If you are looking for an online gaming platform that offers a user-friendly experience, Kheloyar has become a name that many users search for. Whether you're interested in creating a new account, accessing your dashboard through Kheloyaar Login, or learning how to obtain a Kheoyar Id, understanding the platform's features and account process is essential.
            This guide explains everything you need to know about...
            Yesterday, 01:13 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 07-09-2026, 10:04 AM
          0 responses
          17 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-08-2026, 10:08 AM
          0 responses
          10 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-07-2026, 11:05 AM
          0 responses
          25 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-02-2026, 11:08 AM
          0 responses
          31 views
          0 reactions
          Last Post SEQadmin2  
          Working...